Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 489759, 11 pages
http://dx.doi.org/10.1155/2010/489759
Research Article

Regression of Human Prostate Tumors and Metastases in Nude Mice following Treatment with the Recombinant Oncolytic Vaccinia Virus GLV-1h68

1Genelux Corporation, San Diego Science Center, San Diego, CA 92109, USA
2Department of Biochemistry, University of Wuerzburg, D-97074 Wuerzburg, Germany
3Institute for Medical Radiation and Cell Research, University of Wuerzburg, D-97078 Wuerzburg, Germany
4Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, D-97078 Wuerzburg, Germany
5Institute for Molecular Infection Biology, University of Wuerzburg, D-97078 Wuerzburg, Germany
6Department of Radiation Oncology, Moores Cancer Center, University of California, San Diego, 3855 Health Sciences Drive 0843, La Jolla, CA 92093-0843, USA

Received 17 July 2009; Revised 14 October 2009; Accepted 13 January 2010

Academic Editor: Colin Cooper

Copyright © 2010 Ivaylo Gentschev et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. Cheng, H. Zincke, M. L. Blute, E. J. Bergstralh, B. Scherer, and D. G. Bostwick, “Risk of prostate carcinoma death in patients with lymph node metastasis,” Cancer, vol. 91, no. 1, pp. 66–73, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. P. R. Carroll, K. L. Lee, Z. Y. Fuks, and P. W. Kantoff, “Cancer of the prostate,” in Cancer: “Principals and Practices of Oncology”, V. T. DeVita, S. Hellman, and S. A. Rosenberg, Eds., pp. 1418–1479, Lippincott-Raven, New York, NY, USA, 2001. View at Google Scholar
  4. R. Cattaneo, T. Miest, E. V. Shashkova, and M. A. Barry, “Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded,” Nature Reviews Microbiology, vol. 6, no. 7, pp. 529–540, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. J. V. Vähä-Koskela, J. E. Heikkilä, and A. E. Hinkkanen, “Oncolytic viruses in cancer therapy,” Cancer Letters, vol. 254, no. 2, pp. 178–216, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. A. M. Crompton and D. H. Kirn, “From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development,” Current Cancer Drug Targets, vol. 7, no. 2, pp. 133–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. T.-C. Liu, E. Galanis, and D. Kirn, “Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress,” Nature Clinical Practice Oncology, vol. 4, no. 2, pp. 101–117, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. Q. Zhang, Y. A. Yu, E. Wang et al., “Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus,” Cancer Research, vol. 67, no. 20, pp. 10038–10046, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. K. J. Kelly, Y. Woo, P. Brader et al., “Novel oncolytic agent GLV-1h68 is effective against malignant pleural mesothelioma,” Human Gene Therapy, vol. 19, no. 8, pp. 774–782, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. I. Gentschev, J. Stritzker, E. Hofmann et al., “Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent,” Cancer Gene Therapy, vol. 16, no. 4, pp. 320–328, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. Y. A. Yu, C. Galanis, Y. Woo et al., “Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68,” Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 141–151, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. S.-F. Lin, D. L. Price, C.-H. Chen et al., “Oncolytic vaccinia virotherapy of anaplastic thyroid cancer in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 11, pp. 4403–4407, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. S.-F. Lin, Z. Yu, C. Riedl et al., “Treatment of anaplastic thyroid carcinoma in vitro with a mutant vaccinia virus,” Surgery, vol. 142, no. 6, pp. 976–983, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. K. J. Kelly, P. Brader, Y. Woo et al., “Real-time intraoperative detection of melanoma lymph node metastases using recombinant vaccinia virus GLV-lh68 in an immunocompetent animal model,” International Journal of Cancer, vol. 124, no. 4, pp. 911–918, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. N. Chen, Q. Zhang, Y. A. Yu et al., “A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging,” Molecular Medicine, vol. 15, no. 5-6, pp. 144–151, 2009. View at Google Scholar · View at Scopus
  16. P. Brader, K. J. Kelly, N. Chen et al., “Imaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter gene,” Clinical Cancer Research, vol. 15, no. 11, pp. 3791–3801, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. T.-C. Liu and D. Kirn, “Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions,” Cancer Research, vol. 67, no. 2, pp. 429–432, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. S. Weibel, J. Stritzker, M. Eck, W. Goebel, and A. A. Szalay, “Colonization of experimental murine breast tumours by Escherichia coli K-12 significantly alters the tumour microenvironment,” Cellular Microbiology, vol. 10, no. 6, pp. 1235–1248, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. N. Salesi, P. Carlini, E. M. Ruggeri, G. Ferretti, E. Bria, and F. Cognetti, “Prostate cancer: the role of hormonal therapy,” Journal of Experimental and Clinical Cancer Research, vol. 24, no. 2, pp. 175–180, 2005. View at Google Scholar · View at Scopus
  20. N. Craft, Y. Shostak, M. Carey, and C. L. Sawyers, “A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase,” Nature Medicine, vol. 5, no. 3, pp. 280–285, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. N. Craft, C. Chhor, C. Tran et al., “Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process,” Cancer Research, vol. 59, no. 19, pp. 5030–5036, 1999. View at Google Scholar · View at Scopus
  22. E. Brakenhielm, J. B. Burton, M. Johnson et al., “Modulating metastasis by a lymphangiogenic switch in prostate cancer,” International Journal of Cancer, vol. 121, no. 10, pp. 2153–2161, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. S. Mohapatra, B. Chu, X. Zhao, and W. J. Pledger, “Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells,” Cancer Research, vol. 65, no. 17, pp. 7717–7723, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. B. J. Feldman and D. Feldman, “The development of androgen-independent prostate cancer,” Nature Reviews Cancer, vol. 1, no. 1, pp. 34–45, 2001. View at Google Scholar · View at Scopus
  25. E. M. Bruckheimer and N. Kyprianou, “Apoptosis in prostate carcinogenesis: a growth regulator and a therapeutic target,” Cell and Tissue Research, vol. 301, no. 1, pp. 153–162, 2000. View at Google Scholar · View at Scopus
  26. C. W. Knorr, S. D. Allen, A. R. Torres, and D. F. Smee, “Effects of cidofovir treatment on cytokine induction in murine models of cowpox and vaccinia virus infection,” Antiviral Research, vol. 72, no. 2, pp. 125–133, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. A. Worschech, D. Haddad, D. F. Stroncek, E. Wang, F. M. Marincola, and A. A. Szalay, “The immunologic aspects of poxvirus oncolytic therapy,” Cancer Immunology, Immunotherapy, vol. 58, no. 9, pp. 1355–1362, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. A. D. Luster and P. Leder, “IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo,” Journal of Experimental Medicine, vol. 178, no. 3, pp. 1057–1065, 1993. View at Google Scholar · View at Scopus
  29. S. Mahalingam, J. M. Farber, and G. Karupiah, “The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity in vivo,” Journal of Virology, vol. 73, no. 2, pp. 1479–1491, 1999. View at Google Scholar · View at Scopus
  30. X. Zhao, A. Sato, C. S. Dela Cruz et al., “CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer's patch CD11b+ dendritic cells,” Journal of Immunology, vol. 171, no. 6, pp. 2797–2803, 2003. View at Google Scholar · View at Scopus
  31. T. Kitamura, K. Kometani, H. Hashida et al., “SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion,” Nature Genetics, vol. 39, no. 4, pp. 467–475, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus